More importantly, this notion was further supported by the observations in the CDX and PDX models, highlighting the potential of SC75741 in specific NF-κB-targeting therapy for treating the CRC patients with low RNF138 expression and hyperactivation of NF-κB (high pp65 N/C ratio). The gene discussed is RNF138; the disease is colorectal carcinoma.